Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

I-SEE

Financiado

Cell Rejuvenation Therapy for Age-related Macular Degeneration

Age-related macular degeneration (AMD) is a leading cause for blindness, resulting in loss of vision at the center of the visual field - the macula, due to damage to the retina. The disease, usually affecting older adults (>55), w... ver más

30/11/2023

THE HEBREW UNIVERS...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

THE HEBREW UNIVERSITY OF JER...

150.00K€ | Lider

Proyectos interesantes

PID2021-122807OB-C32 TERAPIA CON CELULAS FOTORRECEPTORAS PARA LA REGENERACION DE... 189K€ Cerrado

PID2021-124400OA-I00 IDENTIFICACION DE DIANAS TERAPEUTICAS DERIVADAS DE LOS PERIC... 169K€ Cerrado

SAF2010-21317 ESTRATEGIAS DE RESCATE Y REGENERACION PARA EL TRATAMIENTO DE... 55K€ Cerrado

EIN2019-103021 MODELADO DE UNA RETINA ARTIFICIAL MEDIANTE CELULAS Y TEJIDOS... 12K€ Cerrado

OPTM.RX Novel drug for dry age related macular degeneration 75K€ Cerrado

SAF2010-18977 TRANSPLANTATION OF HUMAN EMBRYONIC STEM CELL AND HUMAN INDUC... 218K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2022-05-03
Fecha Fin: 2023-11-30

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Age-related macular degeneration (AMD) is a leading cause for blindness, resulting in loss of vision at the center of the visual field - the macula, due to damage to the retina. The disease, usually affecting older adults (>55), was diagnosed in 2020 in 196 million people worldwide, with an estimated economic toll of $343 billion including $255 billion in direct healthcare costs. In AMD, photoreceptors and retinal pigmented epithelium (RPE) cells which underlie the photoreceptors undergo degeneration. The standard care is injections of anti-VEGF medicines such as ranibizumab (Lucentis), aflibercept (Eylea) and brolucizumab (Beovu) to the eye every 1-3 months. These delay disease progress but cannot restore lost vision, and have side effects such as bleeding in the eye. During an ERC Starting project, the PI has discovered a new method that would allow to not only delay the disease but to also improve RPE cells function as a treatment for AMD. The proposed approach to rescue RPE cells is rejuvenation by a technique called partial reprogramming. Our results suggest that the proposed technique is safe and efficient in rejuvenating mouse and human fibroblasts, and in improving their function. In the current application, through in vivo studies, we will prepare for implementing our novel approach in our envisioned product I-SEE. In I-SEE, we will aim to use our discovery of a unique combination of factors, that successfully reprogram cells, to drive aging RPE cells into rejuvenation and improved function. We will calibrate the expression of the reprogramming factors in RPE cells, and test rejuvenation and improved function in AMD mouse models. IPR and partnering with clinician and industry will be developed concomitantly. Our final product, I-SEE, is developed based on a PCT patent Application No. 63/210,030, as a cocktail of molecules of mRNA directly applied to the eye, to offer the first AMD treatment that could restore vision.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores